Sign in
Taking peoplePhase 3

Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France10 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
50 people, planned
Started
4 Jun 2024
Expected to end
4 Dec 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • ANAKINRA
Record updated
25 June 2025

Who can take part

Age
6 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Age >= 6 years old with no upper limit
  • Proven FMF according to Livneh international criteria and 2 non ambiguous MEFV mutations
  • Colchicine resistance defined as persistent FMF attack despite the maximum daily posology of colchicine (average one or more attacks per month over a 3-months period); FMF Attack is defined by:
  • Arthritis or
  • Chest pain or
  • Abdominal pain or
  • Myalgia or
  • Erysipelas-like skin lesion Duration of episodes 1-4 days
  • Patient refusing daily anakinra injections-
  • Patients covered at 100% by the health insurance (ALD)
  • Patient who do not have biological inflammation between attacks
  • Written informed consent of the patients and or his legal representatives

Who cannot take part

  • Infection requiring treatment with intravenous antibiotics within 2 weeks prior to inclusion
  • Ongoing chronic treatment with anti IL1 biotherapy since at least 3 months
  • Evidence of active tuberculosis
  • History of recurrent infection (Need more than 4 courses of antibiotic treatment per year (in children) or more >2 times per year (in adults), experience pneumonia twice over any time or >3 bacterial sinusitis in 1 year)
  • Absence of active or latent tuberculosis (no tuberculosis sign on chest X-ray and a negative quantiferon)
  • Contraindication to anakinra (Hypersensitivity to the active substance or to any of the excipients (Citric acid, anhydrous Sodium chloride, Disodium edetate dehydrate, Polysorbate 80, Sodium hydroxide, Water for injections ) or to E. coli derived proteins
  • Patients with neutropenia (ANC <1.5 x 10\^9/l)
  • Inability to provide informed consent
  • Pregnant women
  • Women in labor and nursing mothers
  • Patients in emergency situations and people hospitalized without consent
  • No health care insurance
  • Contraindication to colchicine
  • Patient participating in another interventional clinical trial
  • Patient deprived of liberty
  • Patient under guardianship or curatorship
  • Patient under court protection; Randomization criteria :
  • Negative pregnancy test

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy on clinical symptoms in case of FMF attack among FMF patients resistant to Colchicine of

Read full original descriptionShow less

* on demand anakinra treatment (100 mg/d from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) associated with daily colchicine. * compared to analgesic associated with daily colchicine in patients refusing continuous anti-IL-1 treatment.

The 2 groups in the trial

  • ANAKINRA on DemandTreatment being tested

    On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics

    Treatment: ANAKINRA

  • Standard of CareNo study treatment, for comparison

    Usual analgesics + colchicine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
25 June 2025